These polymorphisms were also associated with both low-grade [(rs2304277 OR<sub>GG</sub> = 3.73, 95% CI = 1.72-8.09) (rs2228001 OR<sub>AC</sub> = 2.18, 95% CI = 1.21-3.92)] and high-grade tumors [(rs2304277 OR<sub>GG</sub> = 3.45, 95% CI = 1.52-7.80) (rs2228001 OR<sub>AC</sub> = 2.81, 95% CI = 1.48-5.33)] as well as with non-muscle-invasive bladder cancer [(rs2304277 OR<sub>GG</sub> = 4.03, 95% CI = 1.87-8.67) (rs2228001 OR<sub>AC</sub> = 2.14, 95% CI = 1.20-3.81)] and muscle-invasive bladder cancer [(rs2304277 OR<sub>GG</sub> = 3.06, 95%CI = 1.31-7.13) (rs2228001 OR<sub>AC</sub> = 2.95, 95%CI = 1.51-5.75)].